MNT: a new target for AML

Key Points • Inducing MNT loss in AMLs driven by MLL-fusion proteins extends survival of transplanted mice, indicative of MNT-dependency.• Inhibiting MNT, a MYC family member, may therefore improve therapy for MLL-driven and perhaps also other AMLs.

• Publication year

  2025

• Venue

  Blood neoplasia

• Publication date

  2025-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bneo.2025.100149PMID 41140443PMCID 12549552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The future of HOXA-expressing leukemias: Menin inhibitor response and resistance

  2023cited by this paper
• Strategies to target the cancer driver MYC in tumor cells

  2023cited by this paper
• MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis

  2023cited by this paper
• Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells

  2023cited by this paper
• Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

  2022cited by this paper
• Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

  2022cited by this paper
• Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?

  2022cited by this paper
• Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

  2022cited by this paper
• Towards precision medicine for AML

  2021cited by this paper
• New Drugs Bringing New Challenges to AML: A Brief Review

  2021cited by this paper
• The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

  2021cited by this paper
• The Multiple Faces of MNT and Its Role as a MYC Modulator

  2021cited by this paper
• Targeting MCL-1 in hematologic malignancies: Rationale and progress.

  2020cited by this paper
• Development and Survival of MYC-driven Lymphomas Requires MYC-Antagonist MNT to Curb MYC-induced Apoptosis.

  2020cited by this paper
• NPM1-mutated acute myeloid leukemia: from bench to bedside.

  2020cited by this paper
• Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial.

  2020cited by this paper
• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

  2020cited by this paper
• MLL fusion proteins and transcriptional control.

  2020cited by this paper
• Epigenetic therapies in acute myeloid leukaemia: where to from here?

  2019cited by this paper
• MYC protein expression is an important prognostic factor in acute myeloid leukemia

  2019cited by this paper
• Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

  2019cited by this paper
• Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

  2019cited by this paper
• Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

  2018cited by this paper
• Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

  2018cited by this paper
• MYC Deregulation in Primary Human Cancers

  2017cited by this paper
• Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia

  2016cited by this paper
• Acute myeloid leukaemia

  2016cited by this paper
• Targeting BCL-2-like Proteins to Kill Cancer Cells.

  2016cited by this paper
• Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice

  2016cited by this paper
• An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.

  2015cited by this paper
• MYC: connecting selective transcriptional control to global RNA production

  2015cited by this paper
• Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.

  2015cited by this paper
• Impact of conditional deletion of the pro-apoptotic BCL-2 family member BIM in mice

  2014cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Cell of origin determines clinically relevant subtypes of MLL-rearranged AML

  2013cited by this paper
• A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis

  2012cited by this paper
• The origin and evolution of mutations in acute myeloid leukemia.

  2012cited by this paper
• Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

  2012cited by this paper
• Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

  2011cited by this paper
• Distinct thresholds govern Myc's biological output in vivo.

  2008cited by this paper
• Of Myc and Mnt

  2006cited by this paper
• Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9

  2006cited by this paper
• Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.

  2006cited by this paper
• Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin

  2005cited by this paper
• Bim is a suppressor of Myc-induced mouse B cell leukemia.

  2004cited by this paper
• Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.

  2004cited by this paper
• Transcriptional activation is a key function encoded by MLL fusion partners

  2003cited by this paper
• Rapid generation of inducible mouse mutants.

  2003cited by this paper
• MLL targets SET domain methyltransferase activity to Hox gene promoters.

  2002cited by this paper
• ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation.

  2002cited by this paper
• MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation.

  2001cited by this paper
• The Myc/Max/Mad network and the transcriptional control of cell behavior.

  2000cited by this paper
• Bim: a novel member of the Bcl‐2 family that promotes apoptosis

  1998cited by this paper
• Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)

  1997cited by this paper
• Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.

  1997cited by this paper
• Ligand-activated site-specific recombination in mice.

  1996cited by this paper
• Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3.

  1995cited by this paper
• Induction of apoptosis in fibroblasts by c-myc protein.

  1992cited by this paper
• Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.

  1991cited by this paper
• Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2

  1990cited by this paper
• Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines.

  1987cited by this paper
• Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)

  1980cited by this paper

• No citing papers are available for this paper.